PULMATRIX, INC. Share-based Payment Arrangement, Expensed and Capitalized, Amount
PULMATRIX, INC. (PULM) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $343.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-14.
Discontinued › Notes › Share-Based Payment Arrangement
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2020-05-14
- PULMATRIX, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2020-03-31 was $343.00K, a 25.27% decline year-over-year.
- PULMATRIX, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2019-12-31 was $331.00K, a 46.18% decline year-over-year.
- PULMATRIX, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2019-09-30 was $185.00K, a 71.97% decline year-over-year.
- PULMATRIX, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2019-06-30 was $1.09M, a 16.93% increase year-over-year.
- PULMATRIX, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2019 was $2.07M, a 30.51% decline from fiscal 2018.
- PULMATRIX, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2018 was $2.97M, a 5.99% increase from fiscal 2017.
- PULMATRIX, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2017 was $2.81M, a 29.84% decline from fiscal 2016.
- PULMATRIX, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2016 was $4.00M.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month |
|---|---|---|---|---|
| 2020-03-31 | $343.00K 10-Q · filed 2020-05-14 | $674.00K derived: sum of 2 quarters · filed 2020-05-14 | $859.00K derived: sum of 3 quarters · filed 2020-05-14 | $1.95M derived: sum of 4 quarters · filed 2020-05-14 |
| 2019-12-31 | $331.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $516.00K derived: sum of 2 quarters · filed 2020-03-26 | $1.61M derived: sum of 3 quarters · filed 2020-03-26 | $2.07M 10-K · filed 2020-03-26 |
| 2019-09-30 | $185.00K 10-Q · filed 2019-11-01 | $1.28M derived: sum of 2 quarters · filed 2019-11-01 | $1.74M 10-Q · filed 2019-11-01 | $2.35M derived: sum of 4 quarters · filed 2020-05-14 |
| 2019-06-30 | $1.09M 10-Q · filed 2019-08-05 | $1.55M 10-Q · filed 2019-08-05 | $2.17M derived: sum of 3 quarters · filed 2020-05-14 | $2.83M derived: sum of 4 quarters · filed 2020-05-14 |
| 2019-03-31 | $459.00K 10-Q · filed 2020-05-14 | $1.07M derived: sum of 2 quarters · filed 2020-05-14 | $1.73M derived: sum of 3 quarters · filed 2020-05-14 | $2.67M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | $615.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $1.27M derived: sum of 2 quarters · filed 2020-03-26 | $2.21M derived: sum of 3 quarters · filed 2020-03-26 | $2.97M 10-K · filed 2020-03-26 |
| 2018-09-30 | $660.00K 10-Q · filed 2019-11-01 | $1.59M derived: sum of 2 quarters · filed 2019-11-01 | $2.36M 10-Q · filed 2019-11-01 | $3.09M derived: sum of 4 quarters · filed 2019-11-01 |
| 2018-06-30 | $933.00K 10-Q · filed 2019-08-05 | $1.70M 10-Q · filed 2019-08-05 | $2.43M derived: sum of 3 quarters · filed 2019-08-05 | $3.17M derived: sum of 4 quarters · filed 2019-08-05 |
| 2018-03-31 | $765.00K 10-Q · filed 2019-05-15 | $1.49M derived: sum of 2 quarters · filed 2019-05-15 | $2.23M derived: sum of 3 quarters · filed 2019-05-15 | $2.94M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $728.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $1.47M derived: sum of 2 quarters · filed 2019-02-19 | $2.18M derived: sum of 3 quarters · filed 2019-02-19 | $2.81M 10-K · filed 2019-02-19 |
| 2017-09-30 | $740.00K 10-Q · filed 2018-11-14 | $1.45M derived: sum of 2 quarters · filed 2018-11-14 | $2.08M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $709.00K 10-Q · filed 2018-08-03 | $1.32M 10-Q · filed 2018-08-03 | ||
| 2017-03-31 | $615.00K 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $4.00M 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |